Hogan, M. J. & Pardi, N. mRNA vaccines within the COVID-19 pandemic and past. Annu. Rev. Med. 73, 17–39 (2022).
Patel, R., Kaki, M., Potluri, V. S., Kahar, P. & Khanna, D. A complete assessment of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum. Vaccines Immunother. 18, 2002083 (2022).
Polack, F. P. et al. Security and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Baden, L. R. et al. Efficacy and security of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Writer(s) et al. COMIRNATY—COVID-19 Vaccine, mRNA Injection, Suspension [Package Insert] Report No. xxxx (Pfizer Laboratories Div Pfizer Inc., 2023).
Writer(s) et al. SPIKEVAX—COVID-19 Vaccine, mRNA Injection, Suspension [Package Insert] Report No. xxxx (Moderna US, Inc., 2023).
Karikó, Okay., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by toll-like receptors: the impression of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
Karikó, Okay. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with elevated translational capability and organic stability. Mol. Ther. 16, 1833–1840 (2008).
Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by varied routes. J. Management. Launch 217, 345–351 (2015).
Alameh, M.-G. et al. Lipid nanoparticles improve the efficacy of mRNA and protein subunit vaccines by inducing sturdy T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021).
Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).
Cullis, P. R. & Hope, M. J. Lipid nanoparticle programs for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017).
Hald Albertsen, C. et al. The position of lipid parts in lipid nanoparticles for vaccines and gene remedy. Adv. Drug Deliv. Rev. 188, 114416 (2022).
Dilliard, S. A. & Siegwart, D. J. Passive, lively and endogenous organ-targeted lipid and polymer nanoparticles for supply of genetic medicine. Nat. Rev. Mater. 8, 282–300 (2023).
Cheng, Q. et al. Selective organ concentrating on (SORT) nanoparticles for tissue-specific mRNA supply and CRISPR–Cas gene modifying. Nat. Nanotechnol. 15, 313–320 (2020).
LoPresti, S. T., Arral, M. L., Chaudhary, N. & Whitehead, Okay. A. The substitute of helper lipids with charged options in lipid nanoparticles facilitates focused mRNA supply to the spleen and lungs. J. Management. Launch 345, 819–831 (2022).
Hassett, Okay. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).
Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles increase the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105–1114 (2023).
Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the supply of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059–1068 (2021).
Chander, N., Basha, G., Cheng, M. H. Y., Witzigmann, D. & Cullis, P. R. Lipid nanoparticle mRNA programs containing excessive ranges of sphingomyelin engender larger protein expression in hepatic and extra-hepatic tissues. Mol. Ther. Strategies Clin. Dev. 30, 235–245 (2023).
Tang, X. et al. Simultaneous dendritic cells concentrating on and efficient endosomal escape improve sialic acid-modified mRNA vaccine efficacy and cut back negative effects. J. Management. Launch 364, 529–545 (2023).
Kim, J. et al. Engineering lipid nanoparticles for enhanced intracellular supply of mRNA by way of inhalation. ACS Nano 16, 14792–14806 (2022).
Zhang, R. et al. Helper lipid construction influences protein adsorption and supply of lipid nanoparticles to spleen and liver. Biomater. Sci. 9, 1449–1463 (2021).
Álvarez-Benedicto, E. et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) supply of messenger RNA (mRNA). Biomater. Sci. 10, 549–559 (2022).
Lam, Okay. et al. Unsaturated, trialkyl ionizable lipids are versatile lipid-nanoparticle parts for therapeutic and vaccine functions. Adv. Mater. 35, 2209624 (2023).
Puthanakit, T. et al. Part II prefusion non-stabilised Covid-19 mRNA vaccine randomised examine. Sci. Rep. 14, 2373 (2024).
Hassett, Okay. J. et al. Influence of lipid nanoparticle dimension on mRNA vaccine immunogenicity. J. Management. Launch 335, 237–246 (2021).
Kirchdoerfer, R. N. et al. Pre-fusion construction of a human coronavirus spike protein. Nature 531, 118–121 (2016).
Leung, A. Okay. Okay., Tam, Y. Y. C., Chen, S., Hafez, I. M. & Cullis, P. R. Microfluidic mixing: a normal technique for encapsulating macromolecules in lipid nanoparticle programs. J. Phys. Chem. B 119, 8698–8706 (2015).
Cheng, M. H. Y. et al. Induction of bleb constructions in lipid nanoparticle formulations of mRNA results in improved transfection efficiency. Adv. Mater. 35, e2303370 (2023).
Mendonça, M. C. P., Kont, A., Kowalski, P. S. & O’Driscoll, C. M. Design of lipid-based nanoparticles for supply of therapeutic nucleic acids. Drug Discov. At this time 28, 103505 (2023).
Li, J. et al. A assessment on phospholipids and their primary functions in drug supply programs. Asian J. Pharm. Sci. 10, 81–98 (2015).
Sallusto, F., Lanzavecchia, A., Araki, Okay. & Ahmed, R. From vaccines to reminiscence and again. Immunity 33, 451–463 (2010).
Laczkó, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits robust mobile and humoral immune responses towards SARS-CoV-2 in mice. Immunity 53, 724–732.e7 (2020).
Verma, C. et al. Most cancers vaccines within the immunotherapy period: promise and potential. Vaccines 11, 1783 (2023).
Tallón de Lara, P., Castañón, H., Sterpi, M. & van den Broek, M. Antimetastatic protection by CD8+ T cells. Tendencies Most cancers 8, 145–157 (2022).
Johansen, P. et al. Antigen kinetics determines immune reactivity. Proc. Natl Acad. Sci. USA 105, 5189–5194 (2008).
Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA supply by selective organ concentrating on nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).
Akinc, A. et al. Focused supply of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).
Kulkarni, J. A., Cullis, P. R. & van der Meel, R. Lipid nanoparticles enabling gene therapies: from ideas to scientific utility. Nucleic Acid Ther. 28, 146–157 (2018).
Bettini, E. et al. Distinct parts of nucleoside-modified messenger RNA vaccines cooperate to instruct environment friendly germinal middle responses. Preprint at bioRxiv https://doi.org/10.1101/2024.05.17.594726 (2024).
Yang, L. et al. Latest advances in lipid nanoparticles for supply of mRNA. Pharmaceutics 14, 2682 (2022).
Remaut, Okay., Lucas, B., Braeckmans, Okay., Demeester, J. & De Smedt, S. C. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J. Management. Launch 117, 256–266 (2007).
Tanaka, H. et al. Enchancment of mRNA supply effectivity to a T cell line by modulating PEG-lipid content material and phospholipid parts of lipid nanoparticles. Pharmaceutics 13, 2097 (2021).
Huang, Y., Jia, A., Wang, Y. & Liu, G. CD8+ T cell exhaustion in anti-tumour immunity: the brand new insights for most cancers immunotherapy. Immunology 168, 30–48 (2023).
Zhu, Y. et al. Screening for lipid nanoparticles that modulate the immune exercise of helper T cells in the direction of enhanced antitumour exercise. Nat. Biomed. Eng. 8, 544–560 (2024).
Bevers, S. et al. mRNA-LNP vaccines tuned for systemic immunization induce robust antitumor immunity by participating splenic immune cells. Mol. Ther. 30, 3078–3094 (2022).
Luozhong, S. et al. Phosphatidylserine lipid nanoparticles promote systemic RNA supply to secondary lymphoid organs. Nano Lett. 22, 8304–8311 (2022).
Gomi, M. et al. Delivering mRNA to secondary lymphoid tissues by phosphatidylserine-loaded lipid nanoparticles. Adv. Healthc. Mater. 12, e2202528 (2023).
Ben-Sasson, S. Z. et al. IL-1 enhances enlargement, effector perform, tissue localization, and reminiscence response of antigen-specific CD8 T cells. J. Exp. Med. 210, 491–502 (2013).
Van Den Eeckhout, B. et al. Particular concentrating on of IL-1β exercise to CD8+ T cells permits for secure use as a vaccine adjuvant. npj Vaccines 5, 64 (2020).
Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity towards tumors. Nat. Med. 15, 1170–1178 (2009).
Baiersdörfer, M. et al. A facile technique for the elimination of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).
Vadovics, M., Muramatsu, H., Sárközy, A. & Pardi, N. Manufacturing and analysis of nucleoside-modified mRNA vaccines for infectious ailments. Strategies Mol. Biol. 2786, 167–181 (2024).
Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine supplies broad safety in mice. Mol. Ther. 28, 1569–1584 (2020).
Heyes, J., Corridor, Okay., Tailor, V., Lenz, R. & MacLachlan, I. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates appropriate to be used in drug supply. J. Management. Launch 112, 280–290 (2006).
Ábrahám, E. et al. Expression and purification of the receptor-binding area of SARS-CoV-2 spike protein in mammalian cells for immunological assays. FEBS Open Bio 14, 380–389 (2024).
Margine, I., Palese, P. & Krammer, F. Expression of purposeful recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus utilizing the baculovirus expression system. J. Vis. Exp. 81, e51112 (2013).
Stevens, J. et al. Construction of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303, 1866–1870 (2004).
Krammer, F. et al. A carboxy-terminal trimerization area stabilizes conformational epitopes on the stalk area of soluble recombinant hemagglutinin substrates. PLoS ONE 7, e43603 (2012).
Parhiz, H. et al. PECAM-1 directed re-targeting of exogenous mRNA offering two orders of magnitude enhancement of vascular supply and expression in lungs unbiased of apolipoprotein E-mediated uptake. J. Management. Launch 291, 106–115 (2018).
